US FDA Backs EPCIS, Refines Advice As November 2023 DSCSA Deadline Approaches

 
• By Bowman Cox

Agency recommends the GS1 standard that stakeholders have been focusing on for working together to remove counterfeits from the US pharmaceutical distribution chain; adds its latest thinking on roles of additional types of trading partners.

On the truck
Further anti-counterfeiting refinements from the fda • Source: Shutterstock

More from Manufacturing

More from Compliance